News

Exagen Inc. Advances Autoimmune Diagnostics with New Biomarkers

Exagen Inc. Advances Autoimmune Diagnostics with New Biomarkers

Exagen Inc. Launches New Biomarkers for Autoimmune Conditions

Exagen Inc., a prominent player in autoimmune diagnostics, has recently made significant strides with the validation and regulatory submission for new biomarkers targeting Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA). This announcement is part of their ongoing efforts to enrich the capabilities of their AVISE CTD platform, ultimately aiming to facilitate better patient care and more accurate diagnoses.

The Importance of Accurate Autoimmune Testing

Accurate autoimmune testing is critical, especially in cases where symptoms are vague and overlap with other conditions. Since its inception in 2012, the AVISE CTD platform has been engineered to provide clarity in diagnosing these connective tissue diseases. With potential ambiguities leading to repeated testing and higher healthcare costs, Exagen’s advancements come at an opportune moment.

Recent Enhancements to AVISE CTD

The enhancements to AVISE CTD include a new T Cell Lupus profile that integrates three novel T Cell biomarkers: TC4d, TIgG, and TIgM. These markers are designed to offer improved sensitivity for SLE compared to earlier SLE biomarkers, thereby allowing healthcare providers to make informed decisions quickly.

New Features for Rheumatoid Arthritis Profiling

Additionally, the RA profile on the AVISE CTD platform will now feature an expanded set of biomarkers added to the existing profile. The introduction of four additional biomarkers, including anti-CarP and anti-RA33 biomarkers in IgA, IgG, and IgM forms, is set to enhance the ability of clinicians to recognize RA, particularly in seronegative patients.

Wider Implications for Autoimmune Disorders

This launch is a leap forward in the realm of autoimmune diagnostics. Many clinicians face challenges when navigating the complexities of autoimmune diseases, which can range from SLE to RA and various other conditions affecting connective tissues. With the AVISE CTD test, rheumatologists and other healthcare professionals have access to a comprehensive array of biomarker assays that can help clarify diagnoses and improve patient outcomes.

A Range of Conditions Addressed

The array of conditions covered by AVISE CTD includes:

  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Sjögren's Disease
  • Mixed Connective Tissue Disease (MCTD)
  • Antiphospholipid Syndrome
  • Myositis
  • Systemic Sclerosis
  • Graves’ Disease
  • Hashimoto’s Thyroiditis

Expert Commentary on the Advancements

According to Dr. Vasileios Kyttaris, an expert in the field, these new biomarkers symbolize an important step forward for clinicians dealing with suspected autoimmune disorders. This expansion not only illuminates the individual patient’s condition more clearly but may lead to swifter and more accurate diagnoses.

Exagen’s commitment to transforming autoimmune healthcare remains at the forefront of its mission. The anticipated availability of these enhancements is subject to approval from the relevant health authorities. This development promises to significantly improve diagnostic journeys for many suffering from autoimmune diseases.

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is dedicated to revolutionizing autoimmune diagnostics, with its headquarters in San Diego County, California. The company’s mission focuses on ensuring clarity in the decision-making processes for autoimmune diseases. Their flagship offering, AVISE CTD, allows better and earlier diagnosis of disorders like lupus and rheumatoid arthritis through its extensive and precise testing portfolio.

Exagen operates a specialized lab that not only diagnoses rheumatic diseases but also provides timely results backed by a variety of AVISE-branded tests aimed at monitoring the disease state. With an ongoing commitment to research and patient-centered care, Exagen plans to keep expanding its capabilities to assist healthcare professionals effectively handle autoimmune conditions.

Frequently Asked Questions

What are the new biomarkers introduced by Exagen Inc.?

Exagen has introduced a new T Cell Lupus profile with three biomarkers and enhancements to the RA profile with four additional biomarkers.

How does the AVISE CTD platform improve patient diagnostics?

The AVISE CTD platform enhances diagnostic clarity by integrating numerous biomarker assays that assist in diagnosing various autoimmune diseases.

What autoimmune diseases are covered by the AVISE CTD test?

The AVISE CTD test covers lupus, rheumatoid arthritis, Sjögren's disease, mixed connective tissue disease, and several others.

What are the anticipated benefits of the new biomarkers?

The new biomarkers are expected to improve sensitivity for SLE and provide clinicians with more data for identifying rheumatoid arthritis.

When will the new AVISE CTD test enhancements be available?

The availability of the new test enhancements is pending conditional approval from health authorities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 118

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 180

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 17

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 71

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 88

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading

Top 5 Most Recently Viewed Articles

Nabors Industries Expands Reach with Parker Wellbore Buyout

Updated Category News Views 205

Nabors Industries Completes Acquisition of Parker Wellbore Nabors Industries Ltd. (NYSE: NBR) has officially concluded its acquisition of Parker Wellbore, a strategic move that strengthens Nabors' leadership in drilling and associated value-added services. This acquisition not only cements Nabors' robust market position but also enhances its service capabilities across...

Continue Reading
Utz, Integer, Arcosa, Dominion: Fair Deals for Shareholders?

Updated Category News Views 18

Investor Concerns Over Recent M&A Deals Today, you can't shake a stick without hitting some M&A news and, frankly, these deals with Utz, Integer, Arcosa, and Dominion have got investors squirming in their seats. With insiders possibly raking in the dough, shareholders are left wondering if they’re just getting table scraps. And you know what makes folks justifiably...

Continue Reading
Revolutionizing Business Growth with QuickBooks AI Tools

Updated Category News Views 151

Revolutionizing Business Growth with QuickBooks AI Tools Software Experts recently spotlighted QuickBooks for its innovative approach in transforming business financial forecasting and planning. The introduction of AI-driven agents in QuickBooks signifies a major transition towards more connected and automated financial management, streamlining processes while enhancing...

Continue Reading
CMB Certification: A New Era for Sustainable Wellness Brands

Updated Category News Views 234

CMB Certification: Pioneering a Path for Wellness Brands Crunchy Mama Box (CMB) has recently unveiled its CMB Certification Program, an initiative that aims to validate wellness brands dedicated to sustainability, ethical practices, and social contributions. This certification serves as a valuable tool for consumers, empowering them to make well-informed decisions while...

Continue Reading
Prevounce Health Integrates AI for Enhanced Patient Care Solutions

Updated Category News Views 303

Prevounce Health Enhances Remote Care with Innovative AI Insights Prevounce Health has recently unveiled an exciting feature that integrates artificial intelligence into its remote care management offerings. This initiative aims to provide AI-generated summaries and personalized recommendations for patients enrolled in remote care management programs, transforming the...

Continue Reading